Ranibizumab refill exchange

Phase 3

Ranibizumab refill exchange is one of 28 therapeutic programs targeting Diabetic Macular Edema. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetic Macular EdemaActive, not recruiting

Diabetic Macular EdemaPhase 3

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Diabetic Macular Edema

#DrugCompanyPhaseTrials

Eylea

Regeneron

Approved

53 2

Vabysmo

Roche

Approved

12 3

Beovu

Novartis

Approved

6 4

Decadron

AAspen Global Incorporated

Approved

13 5

Amaryl

Sanofi

Approved

1 6

Aldactone

Pfizer

Approved

1 7

Kenalog

BBassett Healthcare

Approved

4 8

Klor-Con

Jardiance

1 10

Farxiga

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Diabetic Macular Edema

NCT04108156

Clinical

Trials by Indication[1]

Diabetic Macular Edema1 trial

A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema (Pagoda)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04108156·672 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ranibizumab refill exchange. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ranibizumab refill exchange. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Roche

Ranibizumab refill exchange

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Diabetic Macular Edema1 trial

References

Drug Info

Quick Facts

Related News